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Macrophage Migration Inhibitory Factor Polymorphisms
and Tuberculosis Disease Susceptibility in KwaZuluNatal, South Africa

Max Wang

Background: TB is a leading cause of mortality, infecting over one-third of the world’s
population. Difficulties combating the disease are compounded by the fact that a majority of TB
infections remain in an asymptomatic latent state. Macrophage migration inhibitory factor (MIF)
is an innate cytokine that is encoded in a functionally polymorphic genetic locus with
characterized allelic variants that correlate to TB progression. Understanding the genetic factors
that regulate host immune responses to TB will help to identify individuals who are at higher risk
of severe infection.
Methods: A case-control study of HIV+ active pulmonary TB cases and HIV+ controls with no
history of active TB was conducted on a South African cohort. With informed consent, we
obtained demographics, clinical information, and blood samples for determination of MIF
promoter polymorphisms: a functional -794 CATT5-8 microsatellite, and a closely associated 173 G/C SNP. Serum cytokine levels were quantified using ELISA.
Results: Among 165 enrolled patients (100 cases, 65 controls), 79 were female (40 cases, 39
controls). Aggregate polymorphism assessment revealed non-significant distribution differences
between cases and controls for both the 794 CATT5-8 (p = 0.3316) and -173 G/C (p = 0.7452)
loci. However, stratification by gender reveals a near significant difference in the frequency of
CATT5/5 (p-value = 0.0863) and -173 G/G (p-value = 0.0949) low expresser genotypes in female
cases versus controls but not in males. ELISA showed a significant difference (P = 0.0056) in
serum cytokine levels between cases and controls but not between different polymorphisms.
Conclusions: The results from this study suggest that MIF polymorphisms might contribute to
susceptibility to TB in a sex-dependent manner and that MIF low-expresser genotypes might
confer higher risk for active TB. However, additional studies will need to be done to establish
this relationship.
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Introduction
Tuberculosis (TB) is a highly contagious disease that is transmitted by Mycobacterium
tuberculosis carried in airborne particles generated when individuals who have active untreated
pulmonary or laryngeal disease cough, sneeze, shout, or sing. Only about 10 percent of
subsequently exposed individuals go on to develop an active, symptomatic infection1. Over onethird of the world’s population is infected with M. tuberculosis at any given time. A quarter of
these cases occur in Africa, where an estimated 250,000 individuals die of TB every year. More
than half of new cases occur in individuals already infected with HIV/AIDS1. This is of
particular concern because immune compromised individuals have much higher rates of active
infection, mortality, and increased susceptibility to drug-resistant strains2.
Both the innate and adaptive immune responses play a crucial role in controlling the
development and severity of infection. In healthy individuals, 90% of TB infections remain in a
controlled latent state compared to approximately 60% in immune compromised individuals2.
Therefore, better characterization of the host immune response to TB infection will be necessary
for development of more effective treatment options. Additionally, elements of the immune
response may offer predictive value for disease susceptibility and progression. Animal and
epidemiological studies have identified several immune factors that are implicated in suppressing
TB infections. Some noticeable examples include IFN-γ3, which plays a pivotal and essential
role in protective cellular immunity to tuberculosis infection, and IL-124, whose main role is
activation of antigen-specific lymphocytes in an IFN-γ dependent manner. These results have led
to the use of IFN-γ as a biomarker for tuberculosis diagnosis and treatment monitoring, however,
its use has had limited predictive value5. Additional biomarkers, such as IP-10, MIP-1β, TGF-α,
and VEGF have been proposed for prediction of development of active TB and differentiation of
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active vs. latent infection, but so far none have shown high accuracy for diagnosing infection in
HIV-infected individuals5.
A second line of approach for identifying immune factors important in the host immune
response to TB has been to search for genetic variants in humans that are associated with active
infection. For example, one study showed specific HLA alleles in an Indonesian population were
correlated with progression to active TB infection6. Epidemiological studies in Gambia have also
correlated disease susceptibility to polymorphisms in the natural resistance-associated
macrophage protein (NRAMP1) as well as interleukin-17. In this paper, we will utilize a similar
approach to examine the effects of Macrophage Migration Inhibitory Factor (MIF) gene
polymorphisms on disease susceptibility.
MIF is a cytokine that plays an important role in regulating innate immune and
inflammatory responses in humans and has been linked to both autoimmune and infectious
disease responses. MIF was definitively cloned and recombinant MIF characterized in 1993 by
the Bucala group9. A single gene located on chromosome 22 encodes MIF, which is a 12.5 kD
protein that is highly conserved across species. MIF is produced by T-cells and macrophages,
activates cytokine production, upregulates TLR-4 expression, and suppresses activation-induced
apoptosis of inflammatory cells10. MIF has been shown to have roles both in pathogenic
inflammation and enhanced immunity. Elevated levels of MIF have been linked to sepsis
syndromes, malarial infection, and autoimmune diseases10. In contrast, MIF also has been linked
to enhanced immunity to intracellular microbes, including Leishmania, Salmonella, Toxoplasma,
and Mycobacteria11. The Bucala lab has shown that MIF-deficient mice have lowered cytokine
production and impaired ability to control mycobacterial infection, resulting in a higher
pulmonary bacterial burden and decreased survival12,13. In vitro studies have demonstrated that
MIF inhibits the growth of virulent M. tuberculosis in human macrophages14.
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Four polymorphisms have been identified in the human MIF gene (MIF). In the
promoter region, these include a functional -794 tetranucleotide repeat (CATT5-8) and a -173 G/C
single nucleotide polymorphism (SNP) that is in linkage disequilibrium with CATT15,16. These
polymorphisms can be used to characterize an individual’s MIF expression as either high,
medium, or low. MIF expression genotype also has been correlated with plasma cytokine levels,
with low expression allele patients having lower plasma levels of MIF 13. Studies have shown an
association between MIF polymorphisms and susceptibility to different infectious states. For
example, susceptibility to severe malarial anemia was shown to be partially mediated by MIF
polymorphisms. An association was found between increasing CATT repeats at -794, the -173
CC haplotype, and severity of malarial anemia17. Susceptibility to meningococcal disease18 and
community-acquired pneumonia19 also have been associated with polymorphisms in MIF.
In epidemiological studies carried out by Dr. Bucala’s group, some African and Asian
populations were shown to have a significantly higher prevalence of low-expression MIF alleles
compared to other geographical areas20. It is hypothesized that this trend evolved as a protection
against malaria, given that severe malarial anemia is associated with high-expression alleles17.
However, patients with low expression MIF alleles have been shown to be at significantly
greater risk for high TB bacteremia and are more likely to develop sepsis13. Our present study
was undertaken in South Africa, which has one of the highest incidence rates of tuberculosis in
the world, including both multi-drug-resistant tuberculosis (MDR-TB) and extensively drugresistant tuberculosis (XDR-TB) strains. As such, understanding how TB spreads in the context
of South Africa is critical to combating the disease. Studying how MIF polymorphisms affect
susceptibility to TB in this high incidence area will contribute to the understanding of TB
pathogenesis as well as help inform prevention and treatment programs, allowing for
identification of individuals and groups who are at higher risk of active TB infection.
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Methods
Patient Recruitment
A case-control study design was used to compare MIF polymorphisms between cases
who had microbiologically confirmed TB and controls who had no active or history of active TB.
Patients were enrolled from two different treatment centers in KwaZulu Natal, South Africa: the
Church of Scotland Hospital/Philanjalo NGO in Tugela Ferry and the Greytown MDR-TB
Hospital in Greytown from 10 February 2015 to 5 August 2015. This region of the KZN
province of South Africa is home to approximately 180,000 traditional Zulu people. The
population suffers from high TB incidence (1100/100,000) as well as high HIV prevalence (30%
of antenatal patients). The medical infrastructure that serves this area includes a 350-bed Church
of Scotland Hospital (COSH) and satellite primary health care clinics. Greytown specialized
MDR-TB Hospital is a nearby referral hospital which treats cases of confirmed MDR-TB.
Cases were selected based on the presence of active pulmonary TB, as confirmed by
sputum smear, Gene Xpert, or culture. TB cases were further separated into drug susceptible
(DS-TB) or multi-drug resistant (MDR-TB). In contrast, controls were individuals who had
neither signs of active TB nor history of being on TB treatment. All individuals enrolled were
HIV positive and on or beginning Antiretroviral therapy (ART). All patients provided informed
consent and the studies were approved by the institutional review boards (IRB) at the collecting
institutions and at Yale. Demographic information (age, gender, race, etc.), HIV status and
treatment regimen, CD4 counts, history of TB and treatment, as well as laboratory values and
image results were collected from each patient. In addition, blood samples were collected by a
trained nurse directly into vacutainer tubes, a portion from which serum was separated and
transported to K-RITH to be stored at -80° C. All specimens collected were labeled with study
ID codes only. Names or identifiers were not used on laboratory specimens.
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Genotyping and Serum Analysis
The acquisition and transfer of patient samples to Yale was approved by the providing
institution and the Yale human investigation committee (HIC). DNA was extracted from the red
blood cell fraction using Invitrogen’s Easy DNA extraction kit. Analysis of the MIF promoter
polymorphism, -794 CATT5–8 microsatellite repeat [rs5844572], was carried out by PCR using a
forward primer (5’-TGCAGGAACCAATACCCATAGG-3’) and a fluorescence-labeled reverse
primer (5’-AATGGTAAACTCGGGGGAC-3’). Automated capillary electrophoresis on a DNA
sequencer was performed on the PCR products, and the CATT alleles were identified using
Genotyper version 3.7 software (Applied Biosystems)13. Analysis of the -173 G/C single
nucleotide polymorphism (SNP, rs755622) was carried out using a pre-developed TaqMan assay
for allelic discrimination and analyzed on a Roche 480 Lightcycler real time PCR machine.
Serum MIF levels were measured by sandwich ELISA using specific antibodies13.
Statistical Analysis
Differences in demographic characteristics were analyzed using the Student t test.
Multivariate odds ratios were calculated using logistic regression, controlling for age and sex.
The proportion of MIF genotypic low expressers (CATT5/5 and -173 G/G) as well as the different
allelic combinations of the two polymorphisms in the cases and controls were compared by χ2
analysis. Subsequent χ2 analyses were conducted split by gender. SAS (Statistical Analysis
Software) was used for all statistical calculations.
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Results
Patient Demographics
A total of 165 patients (100 active TB cases, 65 no history of TB controls) were enrolled.
Important clinical and demographic characteristics are listed in Table 1. The median age was 36
years with an IQR of 31-46 for the active cases compared to a median age of 37 with an IQR of
28.5-46 for controls. A significantly higher proportion of controls 39/65 (60%) were female
compared to cases 40/100 (40%), 2-sample z-test; p < 0.05. The median CD4+ T-cell count was
78 for cases (IQR 30.75-163.75) and 207 for controls (IQR 73-480.25). Average CD4+ T-cell
counts were 157.2 cells/µl for cases and 274.5 cells/µl for controls.

Characteristic

HIV+ Active TB

HIV+ No TB

N=

100

65

Age, median years (IQR)

36 (31-46)

37 (28.5-46)

Female Sex

40 (40.0%)

39 (60.0%)

CD4 T-cell count, median
cells/µl (IQR)

78 (30.75-163.75)

207 (73-480.25)

Average (SD)

157.2 (237.3)

274.5 (233.5)

P-value

< 0.05*

Table 1 Clinical and demographic characteristics of subjects.

Genotype Distributions of MIF Polymorphisms
The genotype distribution of MIF-794 CATT5–8 and -173 G/C between the active TB
cases and the no TB controls were found to be non-statistically different, as calculated by chisquared tests for CATT distributions (Table 2, p = 0.3316) and for SNP (Table 3, p = 0.745).
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Table 2 Distribution of MIF -794 CATT5–8 polymorphisms and chi-squared analysis. Outcome: C = control, HIV+
No Active TB; I = case, HIV+ Active Tuberculosis.

Table 3 Distribution of MIF -173 G/C single nucleotide polymorphism and chi-squared analysis. Outcome: C =
control, HIV+ No Active TB; I = case, HIV+ Active Tuberculosis.

Table 4 Logistical regression. Multivariate analysis
adjusting for CATT5/5 genotype (CATT55), -173 G/G
genotype (SNPGG), age, and sex. Gender was found to
significantly predict development of TB (p = 0.0141)
with females being less likely to develop disease (OR
0.448 (0.236-0.851)).

Logistic Regression
Logistic regression was conducted to predict
development of TB from CATT5/5 genotype, -173 G/G genotype, age, and sex (Table 4). Only
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the independent variable of sex was determined to significantly predict development of TB (p =
0.0141) with females being at a lower risk of developing disease (OR = 0.448 (0.236-0.851)).
MIF Polymorphisms Distributions by Gender
Due to the significant predictive value of sex in the logistic regression, we next examined
the distribution and chi-squared statistic for the different polymorphisms separated by gender
(Table 5, Table 6). When separated by gender, the CATT chi-squared p-value drops to 0.1496
for females and 0.2568 for males (Table 5). For SNP distribution, the chi-squared p-value
becomes 0.2379 for females and 0.5099 for males (Table 6).

Table 5 Distribution of MIF -794 CATT5–8 polymorphisms
and chi-squared analysis by gender (left: female; right: male). Outcome: C = control, HIV+ No Active TB; I = case,
HIV+ Active Tuberculosis.
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Table 5 Distribution of MIF -173 G/C single nucleotide polymorphism and chi-squared analysis by gender (left:
female; right: male). Outcome: C = control, HIV+ No Active TB; I = case, HIV+ Active Tuberculosis.

Distribution of CATT5/5 Low-Expresser Genotype in Aggregate and by Gender
The MIF CATT5/5 genotype has been previously correlated with low MIF expression
levels13,15. Aggregate distribution of CATT5/5 showed no statistical significance (p = 0.955)
between cases and controls, as compared using a chi-squared test (Table 6). However, separating
by gender suggested that the frequency of the CATT5/5 low producer genotype is over expressed
in female cases versus controls in an almost significant manner. (Table 7; chi-squared p-value =
0.086). In males, the relationship was inversed with a higher proportion of controls having the
CATT5/5 genotype, although it too was not yet significant (Table 7; chi-squared p-value = 0.100).
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Table 6 Distribution of MIF -794 CATT5/5 genotype and chi-squared analysis. Outcome: C = control, HIV+ No
Active TB; I = case, HIV+ Active Tuberculosis.

Table 7 Distribution of MIF -794 CATT5/5 genotype and chi-squared analysis by gender (left: female; right: male).
Outcome: C = control, HIV+ No Active TB; I = case, HIV+ Active Tuberculosis.
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Distribution of -173 G/G Low-Expresser Genotype in Aggregate and by Gender
The -173 G/G genotype has likewise been associated with low MIF expression21.
Aggregate distribution of -173 G/G also showed no statistical significance (p = 0.4495) between
cases and controls (Table 8; chi-squared p-value = 0.4495). Separating by gender suggested that
female cases had a higher proportion of the -173 G/G genotype, however, it did not reach
statistical significance (Table 9; chi-squared p-value = 0.0949). The male distribution also
returned a non-significant result (Table 9; chi-squared p-value = 0.2515).

Table 8 Distribution of MIF -173 G/G genotype and chi-squared analysis. Outcome: C = control, HIV+ No Active
TB; I = case, HIV+ Active Tuberculosis.

Table 9 Distribution of MIF -173 G/G
genotype and chi-squared analysis by
gender (left: female; right: male).
Outcome: C = control, HIV+ No
Active TB; I = case, HIV+ Active
Tuberculosis.
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MIF Polymorphisms and Serum Cytokine Levels
MIF cytokine levels in serum were measured by sandwich ELISA using specific
antibodies and showed a statistically significant difference between TB cases and non-infected
controls with cases having a higher serum level (Figure 1, 31.9 ng/ml vs 20.9 ng/ml, P = 0.0056).
Neither -794 CATT5–8 nor -173 G/C polymorphisms were found to correlate with MIF cytokine
expression (Figure 2, Figure 4) even after being separated by gender (Figure 3, Figure 5).

Figure 1 MIF cytokine levels (ng/ml) measured using
sandwich ELISA. AT = TB-infected cases. NT = no-TB
= 0.0056
controls. (Mean (SD): AT = P31.9
(27.4), NT = 20.9
(18.4))

Figure 2 MIF cytokine levels (ng/ml) by -794 CATT
genotype and corresponding values.

Figure 3 MIF cytokine levels (ng/ml) by -794 CATT genotype and separated by gender.
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Figure 4 MIF cytokine levels (ng/ml) by -173 G/C genotype and and corresponding values.

Figure 5 MIF cytokine levels (ng/ml) by -173 G/C genotype and separated by gender.

Discussion
Infection with M. tuberculosis results in a wide range of outcomes from asymptomatic
clearance to latent infection to clinical disease and mortality. Understanding how the immune
system influences clinical outcome is crucial for developing new therapeutics and preventative
strategies. Here we utilized a case-control study to examine the effects of functional
polymorphisms in the human gene for MIF on tuberculosis disease susceptibility. We enrolled
cases who were HIV+ and had microbiologically confirmed TB together with controls who were

Wang 16
HIV+ but with no history of TB or TB treatment. South Africa has one of the world's most severe
tuberculosis epidemics, which is compounded by rising drug resistance and HIV co-infection22.
Limiting our study to individuals who were HIV+ allowed us to control for immune-deficiency
status. However, this approach in turn limits the ability of our results to be extrapolated to other
population groups that are not HIV+ or outside of Kwazulu-Natal, South Africa. Even within
South Africa, large genetic differences between ethic groups23 complicate generalization, and
further research is needed to elucidate the effects of MIF polymorphisms on TB susceptibility in
other populations.
Among the patients we recruited, there was a significantly higher proportion of female
controls compared to cases (Table 1). How this sample difference affects the calculated results is
difficult to determine; however, the subsequent analysis with stratification by gender should
have accounted for the discrepancy. The different gender distributions between the cases and
controls might partially explain the non-significant results when the data was taken in aggregate.
When we used logistical regression to model the data, the predictor variables we selected
were age, sex, and the low MIF genotypes CATT5/5 and -173 G/G (Table 4). Besides sex, none
of the other variables were good predictors for development of TB. Other models with differing
combinations of MIF genotypes likewise showed no statistical predictive value (data not shown).
Variables such as CD4 T cell count or HAART treatment history were not included in the model
due to missing or otherwise unreliable data points. These results again highlight the important of
gender when examining the results of our data set. Whether the significance of gender is due to
the distribution of the patients we enrolled or if there is an underlying interaction between gender
and MIF in the context of HIV and TB is a difficult question to answer.
Another limitation of the study that might explain the non-significant results is the small
sample size. Initial calculations gave a conservative minimum required sample size of 210 to
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have enough power to find a significant difference between cases and controls. Our sample size
of 165 limited the power of our study. Additional recruitment or combining with previous
cohorts of patient samples might result in a more significant difference between the two groups
due to an increased sample size.
In summary, genetic analysis of MIF polymorphisms in this population of HIV+
individuals in KwaZulu-Natal, South Africa show no statistical difference in the distribution of
functional MIF polymorphisms between cases who had microbiologically confirmed TB
compared to controls who had no history of TB, both at the -794 CATT5–8 and the -173 G/C
promoter sites (Table 2, Table 3). Stratification by gender showed that the low-expresser
CATT5/5 genotype was overexpressed in female cases vs. controls in a near significant manner (p
= 0.0863, Table 7). In males, the relationship was inversed with controls having a higher
expression of CATT5/5 genotype, however, the difference also was not statistically significant (p
= 0.100, Table 7). Likewise, stratification of -173 G/C distribution by gender suggested that
female controls had a higher proportion of the low-expresser -173 G/G genotype, although only
at a near significant level (p = 0.0949, Table 9). ELISA showed a difference in serum MIF
cytokine levels between cases and controls (Figure 1), which is likely due to TB treatment or
response to infection as opposed to basal genetic expression. No difference in cytokine levels
were found between the different polymorphisms (Figure 2, Figure 4) or by gender (Figure 3,
Figure 5).
The data presented here suggest that there may be a gender-related difference in the
relationship between MIF polymorphisms and TB disease susceptibility. Additional research is
needed to establish whether this relationship persists in other populations or in a larger sample.
Previous studies have shown MIF to have gender-dependent effects24,25, which may partially
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explain the results of this study. Additional research is needed to establish whether this
relationship persists in other populations.
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